ABLE Tx Ltd.

About

Q&A

What is ABLE Tx Ltd.'s primary focus?

ABLE Tx Ltd. is a clinical-stage ophthalmic biopharmaceutical company developing non-invasive, self-applied therapies for vision-threatening retinal and corneal diseases.

What is ABLE Tx Ltd.'s proprietary technology?

ABLE Tx Ltd. utilizes its proprietary Smatrix platform, a miniature, degradable, drug-eluting matrix made from FDA-approved excipients, designed for sustained drug delivery via topical use.

What is the goal of ABLE Tx Ltd.'s Smatrix platform?

The Smatrix platform aims to replace invasive intravitreal injections with first-line, at-home therapies, offering injection-like efficacy through simple topical application.

When was ABLE Tx Ltd. founded?

ABLE Tx Ltd. was founded in 2020.

Who is the CEO and Founder of ABLE Tx Ltd.?

Nir Betser is the CEO and Founder of ABLE Tx Ltd., appointed in May 2020.

Where is ABLE Tx Ltd. headquartered?

ABLE Tx Ltd. is headquartered in Tel Aviv, Israel.

What sector does ABLE Tx Ltd. operate in?

ABLE Tx Ltd. operates primarily in the Biopharma sector, with classifications also in Life Sciences and MedTech.

What specific sub-sector does ABLE Tx Ltd. focus on?

ABLE Tx Ltd. focuses on the Ophthalmology sub-sector.

Team · 2

Nir Betser

Founder · CEO & Founder

Dr. Shay Faitelzon

VP, Operations

Sectors & technology